FDA to review OTC cough medicine safety

The FDA says it's convening an expert panel to review over-the-counter cough and cold medicines for children because of concerns about their safety. The agency began looking into the drugs at the prompting of public health officials worries by reports of hundreds of overdoses and several deaths.

Doctors have asked the FDA to require labels on the products stating that they haven't been proven effective in kids under six. In advance of the planned Oct. 18 meeting, the FDA warned parents not to give cough and cold remedies to children under two without a doctor's approval.

- see the FDA's public health advisory
- read the report from The Washington Post
- here's the Wall Street Journal report (sub. req.)

Suggested Articles

The FDA has found a handful of issues with Biocon’s small molecule API facility in Bengaluru, India.

Pfizer plans to sell two assets to its Mylan-Upjohn spinoff, adding $598 million in revenues—but that won't do much for its profits, analysts warned.

AstraZeneca has made a hefty investment in Brilinta with billions in R&D costs. But will that sunk cost ever turn a profit for the British drugmaker?